Cargando…
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are enriched in oxidative phosphorylation. Here, we report results from a multi-omic analysis of...
Autores principales: | In, Gino K., Ribeiro, Jennifer R., Yin, Jun, Xiu, Joanne, Bustos, Matias A., Ito, Fumito, Chow, Frances, Zada, Gabriel, Hwang, Lindsay, Salama, April K. S., Park, Soo J., Moser, Justin C., Darabi, Sourat, Domingo-Musibay, Evidio, Ascierto, Maria L., Margolin, Kim, Lutzky, Jose, Gibney, Geoffrey T., Atkins, Michael B., Izar, Benjamin, Hoon, Dave S. B., VanderWalde, Ari M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646102/ https://www.ncbi.nlm.nih.gov/pubmed/37964004 http://dx.doi.org/10.1038/s41698-023-00471-z |
Ejemplares similares
-
Personalized Medicine in Oncology; a Special Issue of the Journal of Personalized Medicine
por: VanderWalde, Ari
Publicado: (2021) -
Comparison of Chemotherapy vs Chemotherapy Plus Total Hysterectomy for Women With Uterine Cancer With Distant Organ Metastasis
por: Wang, Yuefeng, et al.
Publicado: (2021) -
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
por: Stein, Matthew K., et al.
Publicado: (2021) -
Prospective Trial of Monocyte Count as a Biomarker of Hand-Foot Syndrome Among Patients With Soft Tissue Sarcomas Treated With Pegylated Liposomal Doxorubicin and Ifosfamide
por: Skubitz, Keith M, et al.
Publicado: (2022) -
Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
por: Skubitz, Keith M., et al.
Publicado: (2022)